4.7 Article

Prevalence and morphology of leukocyte chemotactic factor 2-associated amyloid in renal biopsies

Journal

KIDNEY INTERNATIONAL
Volume 77, Issue 9, Pages 816-819

Publisher

NATURE PUBLISHING GROUP
DOI: 10.1038/ki.2010.9

Keywords

amyloid; LECT2; leukocyte chemotactic factor 2; renal biopsy

Funding

  1. National Cancer Institute [CA 10056]

Ask authors/readers for more resources

Renal pathologists identify the protein component of renal amyloid deposits by immunohistochemistry using antibodies against known amyloidogenic proteins. The majority of amyloid cases can be categorized by a simple antibody panel that includes immunoglobulin light chains lambda and kappa, and serum amyloid A. In some instances, however, these reagents do not recognize materials that stain with Congo red or yield ambiguous staining results, thus creating a diagnostic dilemma. Chemical analysis of fibrils extracted from such a nonreactive renal biopsy led to the discovery of a previously unknown amyloid formed from leukocyte chemotactic factor 2 (LECT2). Over the past 8 years, we received 285 renal amyloid samples, of which 31 remained unclassified. In an effort to determine whether any of the latter samples were LECT2 related, tandem mass spectrometry was performed. In all, 7 of the 31 cases were identified as an amyloid LECT2 (ALECT2), a finding confirmed immunohistochemically using a LECT2-specific antibody. The deposits strongly stained for Congo red and, in most cases, had distinctive morphological features with diffuse involvement of the interstitium, arteries, and glomeruli. Hence, we believe that ALECT2 represents the third common form of renal amyloidosis. Kidney International (2010) 77, 816-819; doi: 10.1038/ki.2010.9; published online 24 February 2010

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Medicine, Research & Experimental

CD122 signaling in CD8+ memory T cells drives costimulation-independent rejection

David Mathews, Ying Dong, Laura B. Higginbotham, Steven C. Kim, Cynthia P. Breeden, Elizabeth A. Stobert, Joseph Jenkins, J. Yun Tso, Christian P. Larsen, Andrew B. Adams

JOURNAL OF CLINICAL INVESTIGATION (2018)

Article Surgery

The impact of belatacept on third-party HLA alloantibodies in highly sensitized kidney transplant recipients

Ronald F. Parsons, Arslan Zahid, Shalini Bumb, Hannah Decker, Harold C. Sullivan, Frances Eun-Hyung Lee, Idelberto Raul Badell, Mandy L. Ford, Christian P. Larsen, Thomas C. Pearson, Annette M. Jackson, Dong-Feng Chen, Matthew Levine, Malek Kamoun, Robert A. Bray, Howard M. Gebel

AMERICAN JOURNAL OF TRANSPLANTATION (2020)

Article Urology & Nephrology

Light chain only variant of proliferative glomerulonephritis with monoclonal immunoglobulin deposits is associated with a high detection rate of the pathogenic plasma cell clone

Samih H. Nasr, Christopher P. Larsen, Christophe Sirac, Jason D. Theis, Camille Domenger, Sophie Chauvet, Vincent Javaugue, Jonathan J. Hogan, Samar M. Said, Surendra Dasari, Julie A. Vrana, Ellen D. McPhail, Lynn D. Cornell, Eve Vilaine, Ziad A. Massy, Jean-Jacques Boffa, David Buob, Stephanie Toussaint, Thomas Guincestre, Guy Touchard, Vivette D. D'Agati, Nelson Leung, Frank Bridoux

KIDNEY INTERNATIONAL (2020)

Article Surgery

CMV high-risk status and posttransplant outcomes in kidney transplant recipients treated with belatacept

Geeta Karadkhele, Julien Hogan, Wairimu Magua, Weiwen Zhang, Idelberto Raul Badell, Aneesh Mehta, Marshall Lyon, Stephen Pastan, Thomas C. Pearson, Christian P. Larsen

Summary: In CMV high-risk kidney transplant recipients, belatacept-based maintenance immunosuppression may increase the risk of primary CMV infection and prolong the course of viral replication. While patients treated with belatacept showed a trend towards lower graft survival, this conclusion was not statistically significant. Further studies are needed to confirm these findings and explore the relationship between belatacept treatment and CMV outcomes.

AMERICAN JOURNAL OF TRANSPLANTATION (2021)

Editorial Material Immunology

Implications of defective immune responses in SARS-CoV-2 vaccinated organ transplant recipients

Peter S. Heeger, Christian P. Larsen, Dorry L. Segev

Summary: Organ transplant patients exhibit poor immune responses to COVID-19 vaccines, highlighting the need to design specific vaccine strategies to protect this vulnerable population from SARS-CoV-2 infection.

SCIENCE IMMUNOLOGY (2021)

Article Immunology

hlaR: A rapid and reproducible tool to identify eplet mismatches between transplant donors and recipients

Aileen C. Johnson, Joan Zhang, H. Cliff Sullivan, Chris Wiebe, Robert Bray, Howard Gebel, Christian P. Larsen

Summary: Eplet mismatch has an impact on transplant recipient outcomes, and accurate assessment requires high-resolution HLA typing. To simplify eplet analysis, we developed a software tool that can impute high-resolution data from low-resolution data and calculate overall and single molecule eplet mismatch. Compared to existing tools, this tool shows high consistency in eplet mismatch and provides rapid and reproducible imputation and mismatch calculation.

HUMAN IMMUNOLOGY (2022)

Editorial Material Surgery

Great expectations

Kenneth A. Newell, Christian P. Larsen

AMERICAN JOURNAL OF TRANSPLANTATION (2022)

Letter Urology & Nephrology

Cubilin and amnionless protein are novel target antigens in anti-brush border antibody disease

Johann Morelle, Tiffany Caza, Hanna Debiec, Selda Aydin, Aaron Storey, Pierre Ronco, Christopher Larsen

KIDNEY INTERNATIONAL (2022)

Article Immunology

Impact of belatacept and tacrolimus on cytomegalovirus viral load control and relapse in moderate and high-risk cytomegalovirus serostatus kidney transplant recipients

Wairimu Magua, Aileen C. Johnson, Geeta M. Karadkhele, Idelberto R. Badell, Payaswini Vasanth, Aneesh K. Mehta, Kirk A. Easley, Kenneth A. Newell, Joseph B. Rickert, Christian P. Larsen

Summary: Belatacept-treated high-risk kidney transplant recipients showed difficulty in sustaining viral control compared to tacrolimus-treated recipients, indicating the need for modified management protocols or avoidance of initial belatacept use in high-risk recipients.

TRANSPLANT INFECTIOUS DISEASE (2022)

Editorial Material Surgery

Open letter to Bristol Myers Squibb: Belatacept; we aren't done yet

Flavio Vincenti, Klemens Budde, Josep Grinyo, Lionel Rostaing, Allan D. Kirk, Christian P. Larsen

AMERICAN JOURNAL OF TRANSPLANTATION (2023)

Article Urology & Nephrology

Hemolysis-associated hemoglobin cast nephropathy results from a range of clinicopathologic disorders

Zeljko Dvanajscak, Patrick D. Walker, L. Nicholas Cossey, Nidia C. Messias, Christie L. Boils, Michael B. Kuperman, Christopher P. Larsen

KIDNEY INTERNATIONAL (2019)

Article Surgery

Emergency department use among kidney transplant recipients in the United States

Brendan P. Lovasik, Rebecca Zhang, Jason M. Hockenberry, Justin D. Schrager, Stephen O. Pastan, Andrew B. Adams, Sumit Mohan, Christian P. Larsen, Rachel E. Patzer

AMERICAN JOURNAL OF TRANSPLANTATION (2018)

No Data Available